Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy

Laboratory investigation and first clinical case

Ronald R Krueger, Jerome C. Ramos-Esteban, A. John Kanellopoulos

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

PURPOSE: To evaluate the safety and efficacy of staged ultraviolet A (UVA) cross-linking following intrastromal 0.1% riboflavin administration in eyes with advanced corneal edema. METHODS: Ten eye bank corneas divided in two groups (n=5) were placed on a pressurized artificial anterior chamber following Descemet's membrane stripping. Two consecutive corneal pockets (350- and 150-μm depth) were sequentially created using a femtosecond laser. Sequential intrastromal injections of 0.1% riboflavin (0.2 ml) followed by either UVA irradiation (15 mW/cm2) for 7 minutes or exposure to air were performed for each pocket. Corneal clarity and central thickness were measured before and after the two UVA cross-linking steps. The same steps were clinically applied in an 84-year-old woman with bullous keratopathy prior to corneal transplantation and followed for 6 months. RESULTS: The corneal clarity improved in the treated but not the control eyes. The mean central corneal thickness was significantly reduced by 256 μm (ultrasound, P=.0002) and 273 μm (Scheimpflug, P=.0004) in treated eyes, but only 100 μm (ultrasound, P=.048) and 107 μm (Scheimpflug, P=.075) in the control eyes. The clinical treatment of corneal edema showed improved clarity and reduced central corneal thickness from 675 to 550 μm (ultrasound) and 696 to 571 μm (Scheimpflug) at 1 month. Best spectacle-corrected visual acuity improved from finger counting to 20/80 at 1 week and beyond, postponing corneal transplantation for >6 months. CONCLUSIONS: Staged UVA cross-linking (15 mW/cm2) with femtosecond laser facilitated intrastromal 0.1% riboflavin administration may be a safe (no corneal scarring) and effective (marked reduction of edema) temporizing alternative method for managing bullous keratopathy.

Original languageEnglish (US)
JournalJournal of Refractive Surgery
Volume24
Issue number7
StatePublished - Sep 1 2008

Fingerprint

Riboflavin
Corneal Edema
Corneal Transplantation
Lasers
Eye Banks
Descemet Membrane
Anterior Chamber
Cornea
Fingers
Visual Acuity
Cicatrix
Edema
Air
Safety
Injections
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy : Laboratory investigation and first clinical case. / Krueger, Ronald R; Ramos-Esteban, Jerome C.; Kanellopoulos, A. John.

In: Journal of Refractive Surgery, Vol. 24, No. 7, 01.09.2008.

Research output: Contribution to journalArticle

@article{ceb4ce3f2def44f0b57dd19836948408,
title = "Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy: Laboratory investigation and first clinical case",
abstract = "PURPOSE: To evaluate the safety and efficacy of staged ultraviolet A (UVA) cross-linking following intrastromal 0.1{\%} riboflavin administration in eyes with advanced corneal edema. METHODS: Ten eye bank corneas divided in two groups (n=5) were placed on a pressurized artificial anterior chamber following Descemet's membrane stripping. Two consecutive corneal pockets (350- and 150-μm depth) were sequentially created using a femtosecond laser. Sequential intrastromal injections of 0.1{\%} riboflavin (0.2 ml) followed by either UVA irradiation (15 mW/cm2) for 7 minutes or exposure to air were performed for each pocket. Corneal clarity and central thickness were measured before and after the two UVA cross-linking steps. The same steps were clinically applied in an 84-year-old woman with bullous keratopathy prior to corneal transplantation and followed for 6 months. RESULTS: The corneal clarity improved in the treated but not the control eyes. The mean central corneal thickness was significantly reduced by 256 μm (ultrasound, P=.0002) and 273 μm (Scheimpflug, P=.0004) in treated eyes, but only 100 μm (ultrasound, P=.048) and 107 μm (Scheimpflug, P=.075) in the control eyes. The clinical treatment of corneal edema showed improved clarity and reduced central corneal thickness from 675 to 550 μm (ultrasound) and 696 to 571 μm (Scheimpflug) at 1 month. Best spectacle-corrected visual acuity improved from finger counting to 20/80 at 1 week and beyond, postponing corneal transplantation for >6 months. CONCLUSIONS: Staged UVA cross-linking (15 mW/cm2) with femtosecond laser facilitated intrastromal 0.1{\%} riboflavin administration may be a safe (no corneal scarring) and effective (marked reduction of edema) temporizing alternative method for managing bullous keratopathy.",
author = "Krueger, {Ronald R} and Ramos-Esteban, {Jerome C.} and Kanellopoulos, {A. John}",
year = "2008",
month = "9",
day = "1",
language = "English (US)",
volume = "24",
journal = "Journal of Refractive Surgery",
issn = "0883-0444",
publisher = "Slack Incorporated",
number = "7",

}

TY - JOUR

T1 - Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy

T2 - Laboratory investigation and first clinical case

AU - Krueger, Ronald R

AU - Ramos-Esteban, Jerome C.

AU - Kanellopoulos, A. John

PY - 2008/9/1

Y1 - 2008/9/1

N2 - PURPOSE: To evaluate the safety and efficacy of staged ultraviolet A (UVA) cross-linking following intrastromal 0.1% riboflavin administration in eyes with advanced corneal edema. METHODS: Ten eye bank corneas divided in two groups (n=5) were placed on a pressurized artificial anterior chamber following Descemet's membrane stripping. Two consecutive corneal pockets (350- and 150-μm depth) were sequentially created using a femtosecond laser. Sequential intrastromal injections of 0.1% riboflavin (0.2 ml) followed by either UVA irradiation (15 mW/cm2) for 7 minutes or exposure to air were performed for each pocket. Corneal clarity and central thickness were measured before and after the two UVA cross-linking steps. The same steps were clinically applied in an 84-year-old woman with bullous keratopathy prior to corneal transplantation and followed for 6 months. RESULTS: The corneal clarity improved in the treated but not the control eyes. The mean central corneal thickness was significantly reduced by 256 μm (ultrasound, P=.0002) and 273 μm (Scheimpflug, P=.0004) in treated eyes, but only 100 μm (ultrasound, P=.048) and 107 μm (Scheimpflug, P=.075) in the control eyes. The clinical treatment of corneal edema showed improved clarity and reduced central corneal thickness from 675 to 550 μm (ultrasound) and 696 to 571 μm (Scheimpflug) at 1 month. Best spectacle-corrected visual acuity improved from finger counting to 20/80 at 1 week and beyond, postponing corneal transplantation for >6 months. CONCLUSIONS: Staged UVA cross-linking (15 mW/cm2) with femtosecond laser facilitated intrastromal 0.1% riboflavin administration may be a safe (no corneal scarring) and effective (marked reduction of edema) temporizing alternative method for managing bullous keratopathy.

AB - PURPOSE: To evaluate the safety and efficacy of staged ultraviolet A (UVA) cross-linking following intrastromal 0.1% riboflavin administration in eyes with advanced corneal edema. METHODS: Ten eye bank corneas divided in two groups (n=5) were placed on a pressurized artificial anterior chamber following Descemet's membrane stripping. Two consecutive corneal pockets (350- and 150-μm depth) were sequentially created using a femtosecond laser. Sequential intrastromal injections of 0.1% riboflavin (0.2 ml) followed by either UVA irradiation (15 mW/cm2) for 7 minutes or exposure to air were performed for each pocket. Corneal clarity and central thickness were measured before and after the two UVA cross-linking steps. The same steps were clinically applied in an 84-year-old woman with bullous keratopathy prior to corneal transplantation and followed for 6 months. RESULTS: The corneal clarity improved in the treated but not the control eyes. The mean central corneal thickness was significantly reduced by 256 μm (ultrasound, P=.0002) and 273 μm (Scheimpflug, P=.0004) in treated eyes, but only 100 μm (ultrasound, P=.048) and 107 μm (Scheimpflug, P=.075) in the control eyes. The clinical treatment of corneal edema showed improved clarity and reduced central corneal thickness from 675 to 550 μm (ultrasound) and 696 to 571 μm (Scheimpflug) at 1 month. Best spectacle-corrected visual acuity improved from finger counting to 20/80 at 1 week and beyond, postponing corneal transplantation for >6 months. CONCLUSIONS: Staged UVA cross-linking (15 mW/cm2) with femtosecond laser facilitated intrastromal 0.1% riboflavin administration may be a safe (no corneal scarring) and effective (marked reduction of edema) temporizing alternative method for managing bullous keratopathy.

UR - http://www.scopus.com/inward/record.url?scp=51149115767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51149115767&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Journal of Refractive Surgery

JF - Journal of Refractive Surgery

SN - 0883-0444

IS - 7

ER -